|
DUBLIN, March 7, 2024 /PRNewswire/ -- The "Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
The latest comprehensive analysis of the global hemophilia market forecasts a significant growth trajectory, with an expectation to reach US$17.76 billion by 2028. This positive surge represents a compound annual growth rate (CAGR) of 5.81% over the 2024-2028 period.
The current expansion in the hemophilia market is primarily driven by a suite of influential factors. Highlighting these are the increasing expenditure within the healthcare sector, a noted rise in the identified patient volume with hemophilia, and a growing emphasis on prophylactic treatments over on-demand options. Moreover, demographic shifts, notably a rise in the male population—the gender predominantly affected by hemophilia—are contributing to the upward trend, alongside supportive government initiatives designed to improve patient outcomes.
However, the market is not without challenges. These include the high costs associated with hemophilia treatments and a degree of resistance among patients and healthcare providers to switch to newer, potentially more effective therapies. In response, the market is expected to witness stimulating trends, such as the development of groundbreaking hemophilia treatments and the increasing prominence of gene therapy as a viable treatment option.
Market Segmentation Insights
In terms of treatment regimens, the market divides into prophylaxis and on-demand therapies. Prophylaxis therapy continues to account for the lion's share of the market, emphasizing its emergence as a standard care protocol for those living with hemophilia. When dissected by type, hemophilia A remains the more prevalent form, thus dominating the market scene. Additionally, replacement therapy currently takes precedence over Immune Tolerance Induction (ITI) therapy, reflecting the widespread use of this traditional treatment approach.
The regional analysis of the hemophilia market indicates that North America leads the charge, with Europe and Asia Pacific following suit. This dominant standing of the North American market is fueled by an amalgam of factors, including a higher prevalence of the disorder, greater awareness of treatment methodologies, and a pronounced preference for prophylactic treatments.
Strategic Analysis of Competitive Landscape
The continuously evolving competitive landscape of the global hemophilia market receives detailed attention in the report. Brief profiles of leading market players—spanning from established pharmaceutical giants to emerging biotech firms—provide a kaleidoscopic view of strategies, positioning, and potential growth opportunities. The report aims to furnish stakeholders with a rigorous inquiry into the operative dynamics and forecasts of the hemophilia market.
Value to Key Stakeholders
- Hemophilia Drugs Manufacturers: For entities involved in the formulation and distribution of hemophilia treatments, this report offers a vital compass charting current market positions and future directions.
- API Suppliers: Manufacturers and distributors of Active Pharmaceutical Ingredients (API) will find the segmented market analysis crucial for strategic planning and opportunity assessment.
- End Users (Hospital, Medical Centers, Clinical Institutes): Healthcare facilities and professionals stand to gain from insights into the evolving hemophilia treatment paradigms and patient care advancements.
- Healthcare Consulting Firms: Consultancies dedicated to healthcare can leverage this report's findings to advise clients with the most current and comprehensive market knowledge.
- Investment Banks: Financial institutions will find the report's projections invaluable for guiding investment strategies in the biopharmaceutical sector.
- Government Bodies & Regulating Authorities: Policymakers and regulating entities can utilize the in-depth market insights to inform policy and regulatory frameworks.
Key Topics Covered:
1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
1.3 Signs & Symptoms
1.4 Diagnosis of Hemophilia
1.5 Treatment of Hemophilia
2. Impact of COVID-19
2.1 Impact on Global Economy
2.2 Global Prevalence of COVID-19
2.3 Impact on Healthcare Spending
2.4 Post-COVID Scenario
3. Global Market Analysis
3.1 Global Hemophilia Market by Value
3.2 Global Hemophilia Market Forecast by Value
3.3 Global Hemophilia Market by Treatment Regimen
3.4 Global Hemophilia Market by Type
3.4.1 Global Hemophilia A Market Forecast by Value
3.4.2 Global Hemophilia A Market by Severity
3.4.3 Global Hemophilia A Market by Treatment Type
3.4.4 Global Hemophilia A Market by Treatment Regimen
3.4.5 Global Hemophilia A Market Value by Treatment Regimen
3.4.6 Global Hemophilia B Market Forecast by Value
3.4.7 Global Hemophilia B Market by Severity
3.4.8 Global Hemophilia B Market by Treatment Type
3.4.9 Global Hemophilia B Market by Treatment Regimen
3.4.10 Global Hemophilia B Market Value by Treatment Regimen
3.5 Global Hemophilia Market by Therapy
3.5.1 Global Hemophilia Replacement Therapy Market Forecast by Value
3.5.2 Global Hemophilia ITI Therapy Market Forecast by Value
3.6 Global Hemophilia Market by Region
4. Regional Market Analysis
4.1 North America
4.1.1 North America Hemophilia Market by Value
4.1.2 North America Hemophilia Market Forecast by Value
4.1.3 The US Hemophilia Market by Value
4.1.4 The US Hemophilia Market Forecast by Value
4.1.5 The US Hemophilia Market by Type
4.1.6 The US Hemophilia A Market Forecast by Value
4.1.7 The US Hemophilia A Treated Patient Volume Forecast
4.1.8 The US Hemophilia A Severe Patients on Prophylactic Therapy
4.1.9 The US Hemophilia A Severe Patients on On-Demand Therapy
4.1.10 The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy
4.1.11 The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy
4.1.12 The US Hemophilia B Market Forecast by Value
4.1.13 The US Hemophilia B Treated Patients Volume Forecast
4.1.14 The US Hemophilia B Severe Patients on Prophylaxis Therapy
4.1.15 The US Hemophilia B Severe Patients on On-Demand Therapy
4.1.16 The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy
4.1.17 The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy
4.2 Europe
4.2.1 Europe Hemophilia Market by Value
4.2.2 Europe Hemophilia Market Forecast by Value
4.2.3 Europe Hemophilia Patient Volume Forecast
4.2.4 Europe Hemophilia A Patient Volume Forecast
4.2.5 Europe Hemophilia B Patient Volume Forecast
4.3 Asia Pacific
4.3.1 Asia Pacific Hemophilia Market by Value
4.3.2 Asia Pacific Hemophilia Market Forecast by Value
4.4 ROW
4.4.1 ROW Hemophilia Market by Value
4.4.2 ROW Hemophilia Market Forecast by Value
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increased Focus on Prophylactic Treatment
5.1.2 Increasing Diagnosis Rate
5.1.3 Rise in Global Healthcare Expenditure
5.1.4 Rise in Male Population
5.1.5 Favourable Government Initiatives
5.2 Key Trends & Development
5.2.1 Shifting Focus to Extended Half Life Therapies
5.2.2 Development of Novel Hemophilia Treatments
5.2.3 Popularity of Gene Therapy
5.3 Challenges
5.3.1 High Cost of Treatment
5.3.2 Reluctance to Switch to New Therapies
6. Competitive Landscape
6.1 Global Market
6.1.1 Global Hemophilia A Market Share by Company
6.1.2 Global Hemophilia A Factor VIII Products Market Share by Company
6.1.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
6.1.4 Global Hemophilia B Market Share by Company
6.1.5 Global Hemophilia B Factor IX Products Market Share Forecast
6.1.6 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
6.2 The US Market
6.2.1 The US Hemophilia A Market Share by Company
6.3 Europe Market
6.3.1 Europe Hemophilia A Market Share by Company
7. Company Profiles
7.1 Pfizer Inc.
7.2 Bayer Group
7.3 Sanofi S.A.
7.4 Takeda Pharmaceutical Company
7.5 Novo Nordisk
7.6 CSL Limited
For more information about this report visit https://www.researchandmarkets.com/r/4w7pat
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
 View original content:https://www.prnewswire.com/news-releases/global-hemophilia-market-analysis-report-2023-2028-increased-focus-on-prophylactic-treatment-and-shifting-focus-to-extended-half-life-therapies-302082845.html
SOURCE Research and Markets
|
